ART (assisted reproductive technology) is the umbrella term for fertility treatments that handle eggs, sperm, or embryos outside the body; IVF is one such technique, alongside ICSI, IUI, PGT, frozen embryo transfer (FET), and egg freezing — 6 technologies across 47 regulatory systems via 10 decision nodes. Over 12 million babies worldwide (US >1 million, Europe >3 million) have been born through ART since 1978 (ESHRE 2025).
Sources: CDC 2023 ART Surveillance Report, SART 2024 National Summary, ESHRE 2025 European ART Monitoring, HFEA 2023/2024, ASRM 2025 Practice Guidelines
What Is ART?
ART is the top-level fertility category; what counts as ART marks which options need a laboratory. The US CDC defines it:
“Assisted reproductive technology (ART) is the term for all fertility-boosting procedures in which a woman’s eggs, a man’s sperm, or her embryos are handled outside the body.” — U.S. Centers for Disease Control and Prevention, ART definition
The defining trait — eggs or embryos undergo at least one lab step — separates ART from ovulation-induction drugs.
| Technology Layer | Representative Technique | In Vitro Step | Complexity | Population Share |
|---|---|---|---|---|
| Basic | IUI (stimulation + insemination) | Sperm washing | Low | ~25% |
| Core | IVF (1st generation) | Egg-sperm co-incubation | Moderate | ~35% |
| Precision | ICSI (2nd generation) | Single sperm injection | High | ~30% |
| Screening | PGT (3rd generation) | Embryo biopsy + genetic test | Highest | ~10% |
| Extended | FET, egg freezing, donor, surrogacy | Cryopreservation / third-party | Moderate | ~15% (overlap) |
The ladder runs least to most invasive: ovulation induction, IUI (sperm washing is the first ART step), IVF/ICSI, PGT, then donor eggs or surrogacy.
How Do the 6 Major ART Technologies Compare?
IUI — Intrauterine Insemination
| Dimension | Data |
|---|---|
| Live birth per cycle | 8–15% (US 8–12%, Europe 7–12%; natural ~5–8%, stimulated ~10–15%) |
| 3-cycle cumulative live birth | 25–40% |
| Average cost (US) | $400–$1,500/cycle |
| Requirements | ≥1 patent tube, mild male factor, unexplained infertility |
| Not suitable for | Bilateral tubal blockage, severe male factor, moderate-severe endometriosis |
| Multiples (stimulated) | 8–15% |
| Cycle length | 2–4 weeks |
The standard ladder is 3 IUI cycles (25–35% cumulative live birth under 35) then IVF: after 3 failed cycles, moving to IVF yields rates no different from direct IVF (Cochrane 2024), while above 38 IUI falls below 8% per cycle and severe male factor bypasses it.
Conventional IVF — 1st Generation
| Dimension | Data |
|---|---|
| Live birth per cycle (<35) | 45–55% |
| Live birth per cycle (35–37) | 35–42% |
| Live birth per cycle (38–40) | 20–30% |
| Live birth per cycle (>40) | 5–15% |
| Cumulative birth (3 cycles, <35) | >70% |
| Average cost (US) | $12,000–$18,000/cycle |
| Average cost (Thailand) | $6,000–$9,000/cycle |
| Suitable for | Tubal factor, ovulation disorders, mild male factor, unexplained |
| Fresh-transfer multiples | ~15–25% (US 12–18%, Europe 10–16%) |
| eSET live birth | 40–50% (good blastocyst) |
| eSET multiples | <5% (US, Europe <3%) |
| Severe OHSS | 0.5–2% (US 0.3–1%, Europe 0.5–1.5%) |
| Condition | Recommendation | Rationale |
|---|---|---|
| Confirmed male factor | ICSI | Fertilization improves 30–40 percentage points |
| Prior IVF fertilization <50% | ICSI | Avoids recurrent fertilization failure |
| Unexplained infertility | Conventional IVF | ICSI adds cost without live-birth benefit |
| Low reserve (<5 eggs) | ICSI preferred | Maximizes fertilization of few eggs |
| PGT cycle | ICSI | Avoids sperm DNA contamination |
ICSI — Intracytoplasmic Sperm Injection
In the US about 70% of IVF cycles use ICSI (CDC 2023), even without a confirmed male-factor diagnosis.
| Dimension | Data |
|---|---|
| Fertilization rate | 75–85% (US 75–82%; vs IVF 55–65%) |
| Total fertilization failure | <2% (vs conventional IVF 5–10%) |
| Additional cost | $1,000–$2,000 (US) |
| Indications | Severe oligoasthenoteratozoospermia, obstructive azoospermia, prior fertilization failure |
Live birth per intended egg retrieval (all transfers, SART 2023) tracks conventional IVF at every age without significant difference (<35: 48–53% vs 50–55%; 35–37: 36–40% vs 38–42%; 38–40: 21–27% vs 22–28%; >40: 7–12% vs 8–12%), and without male factor ICSI neither improves live birth nor justifies itself — adding it is risk hedging against fertilization failure, not an efficacy gain.
PGT — Preimplantation Genetic Testing
PGT moves ART from treating infertility toward selecting embryos, in three subcategories:
| Type | Target | Indications | Extra cost (US) |
|---|---|---|---|
| PGT-A | Chromosomal aneuploidy screening | Advanced age, recurrent miscarriage, RIF | $3,000–$5,000 |
| PGT-M | Monogenic disease testing | Known mutation carriers | $5,000–$10,000 probe + $500–$1,000/embryo |
| PGT-SR | Structural rearrangements | Balanced translocation | Same as PGT-A + counseling |
| Age | Euploid | Aneuploid | Miscarriage risk ↓ |
|---|---|---|---|
| <30 | ~75% | ~25% | ~30% |
| 30–34 | ~65% | ~35% | ~35% |
| 35–37 | ~55% | ~45% | ~40% |
| 38–40 | ~40% | ~60% | ~45% |
| 41–42 | ~25% | ~75% | ~50% |
| >42 | ~15% | ~85% | ~50% |
PGT-A’s value depends on blastocyst count; see Decision Node 4.
FET, or Frozen Embryo Transfer, vs Fresh Transfer
| Dimension | Fresh Transfer | Frozen Transfer (FET) |
|---|---|---|
| Single-transfer live birth | 40–50% (good blastocyst) | 45–55% (good blastocyst) |
| Cumulative live birth | All embryos in cycle | Frozen embryo count |
| OHSS risk | Present (stimulation cycle) | Nearly zero |
| Time from retrieval | 3–5 days | 1–3 months |
| Extra cost | None | $500–$1,000 (freezing) |
| Best for | Endometrium >7mm, E2 <3,000 pg/mL, low OHSS risk | Freeze-all indications (OHSS risk, PGT, endometrial factors) |
For PCOS patients, FET live birth exceeded fresh transfer (55% vs 42%, Lancet 2024); non-PCOS normal responders showed no significant difference.
Egg Freezing and Fertility Preservation
| Dimension | Data |
|---|---|
| Vitrification survival | >95% (mature eggs) |
| Post-thaw fertilization | 70–80% (ICSI required) |
| Birth per frozen egg | ~5–8% (age-stratified) |
| Recommended (<35) | 15–20 eggs (≥80% chance of ≥1 birth) |
| Recommended (35–38) | 20–30 eggs |
| Average cost (US) | $8,000–$15,000 retrieval + $500–$1,000/year storage |
| Indications | Elective preservation, pre-chemo, pre-ovarian surgery |
How Do ART Regulations and Costs Vary by Country?
Availability differs dramatically across borders, compared below by legal framework, cost, and reported success.
A Four-Quadrant Regulatory Model
Quadrant I: Liberal & accessible (best for cross-border care)
| Country | Egg Donation | Surrogacy | PGT | LGBT Access | Cost per Cycle (USD) |
|---|---|---|---|---|---|
| United States | ✅ | ✅ (commercial states) | ✅ | ✅ (some states) | $12,000–$18,000 |
| Greece | ✅ | ✅ (altruistic) | ✅ | ✅ | $5,000–$8,000 |
| Spain | ✅ | ❌ | ✅ | ✅ | $5,000–$8,000 |
| Mexico | ✅ | ✅ | ✅ | ✅ | $4,000–$7,000 |
Quadrant II: Liberal but high cost — United Kingdom (HFEA-regulated) and Australia (partial Medicare coverage).
Quadrant III: Restrictive but accessible — China (egg donation and surrogacy banned, married couples only), Germany (egg donation banned, PGT restricted), Italy (surrogacy banned, egg donation partial).
Quadrant IV: Restrictive & low accessibility — Afghanistan, Yemen, parts of Africa: ART largely unavailable.
Global IVF Cost Comparison — single cycle, USD
| Country | Base IVF | With meds | +ICSI | +PGT-A |
|---|---|---|---|---|
| United States | $12,000–$18,000 | $18,000–$25,000 | $1,000–$2,000 | $3,000–$5,000 |
| United Kingdom | $9,000–$14,000 | $11,000–$17,000 | $1,200–$2,500 | $3,000–$5,000 |
| Australia | $7,000–$11,000 | $9,000–$14,000 | $800–$1,500 | $2,500–$4,500 |
| Spain | $5,000–$8,000 | $6,500–$10,000 | $500–$1,200 | $2,000–$3,500 |
| Greece | $5,000–$8,000 | $6,000–$9,500 | $500–$1,200 | $2,000–$3,500 |
| Thailand | $6,000–$9,000 | $7,000–$11,000 | $600–$1,500 | $2,000–$4,000 |
| India | $3,000–$6,000 | $4,000–$7,500 | $300–$800 | $800–$2,000 |
| Turkey | $3,000–$5,000 | $4,000–$7,000 | $400–$1,000 | $1,500–$3,000 |
Costs vary by hospital, city, and protocol (2025–2026 pricing).
ART Success Rates by Country
| Country | <35 per retrieval | 35–37 | 38–40 | >40 | eSET rate | Source |
|---|---|---|---|---|---|---|
| United States | 48–55% | 35–40% | 21–27% | 5–11% | ~55% | CDC 2023 |
| United Kingdom | 42–50% | 32–38% | 18–24% | 5–10% | ~65% | HFEA 2023 |
| Australia | 40–48% | 30–37% | 18–22% | 5–9% | ~70% | ANZARD 2023 |
| Spain | 45–52% | 33–40% | 20–25% | 6–12% | ~55% | SEF 2023 |
| Japan | 35–45% | 28–35% | 16–22% | 4–8% | ~80% | JSRE 2024 |
Comparisons must account for reporting standards (per retrieval vs per transfer), patient mix, and embryo-count limits.
Which Decisions Matter Most? 10 Key Nodes
Each node below is a quantified decision tool.
Decision Node 1: Do You Need ART?
| Scenario | Recommended Path | Rationale |
|---|---|---|
| <35, infertility <1 year | Keep trying → 3 IUI cycles | Natural birth still likely |
| <35, infertility >1 year | Workup → 3 IUI cycles | Begin ART after diagnosis |
| 35–38, >6 months | Expedited workup → 2 IUI → IVF | Age window limited |
| >38, >6 months | Direct IVF | IUI birth <5%/cycle |
| Bilateral tubal blockage | Direct IVF | IUI ineffective |
| Severe male factor | Direct ICSI | IUI and conventional IVF both ineffective |
IUI-vs-IVF scoring matrix — score ≥3 → direct IVF; score 0–2 → IUI × 3 then reassess.
| Assessment | Scoring | Your Score |
|---|---|---|
| Age | >38=2, 35–38=1, <35=0 | — |
| Infertility duration | >3yr=2, 1–3yr=1, <1yr=0 | — |
| Tubal status | Bilateral block/hydrosalpinx=2, unilateral=1, normal=0 | — |
| Male factor | Severe=2, mild-moderate=1, normal=0 | — |
| Prior IUI failures | ≥2=1, 0–1=0 | — |
| Total | — | ___ |
Decision Node 2: Which ART Technique — IVF vs ICSI vs IUI?
Use the tables above; start with the simplest feasible option within the age window.
Decision Node 3: Own Eggs or Donor Eggs?
| Factor | Own eggs | Donor eggs |
|---|---|---|
| <35 | 45–55% | 50–60% |
| 35–38 | 35–42% | 50–60% |
| 38–40 | 20–30% | 45–55% |
| >40 | 5–15% | 40–55% |
| Genetic relationship | Full | None |
| Legal complexity | Low | Moderate-high |
| Cost increment | Baseline | +$15,000–$30,000 (US) |
Favoring donor eggs: age >42 with a prior failed own-egg cycle, AMH below 0.5 ng/mL with ≤3 eggs, poor embryo development across ≥2 cycles, or primary ovarian insufficiency.
Decision Node 4: Should You Do PGT-A?
| Blastocysts available | Expected euploid (age 38) | Recommendation |
|---|---|---|
| 1 | 0–1 | Skip (biopsy attrition > benefit) |
| 2–3 | 1–2 | Discuss with physician |
| ≥4 | ≥2 | Strongly recommended |
Decision Node 5: Fresh Transfer or Freeze-All?
| Condition | Fresh Score | FET Score |
|---|---|---|
| Endometrial thickness <7mm | −2 | +2 |
| E2 ≥3,000 pg/mL | −2 | +2 |
| PGT cycle | −3 | +3 |
| High OHSS risk | −3 | +3 |
| PCOS diagnosis | −1 | +1 |
| Age <35 | +1 | 0 |
Decision Node 6: Single or Double Embryo Transfer?
| Condition | Recommended Embryos | Live Birth/Cycle | Multiple Rate |
|---|---|---|---|
| <35, good blastocyst | 1 | 45–50% | <2% |
| <35, average quality | 1 | 30–40% | <2% |
| 35–37, good | 1 | 35–45% | <2% |
| 35–37, average | 1 (discuss 2) | 25–35% | 2–3% |
| 38–40 | 1–2 | 20–35% | 5–15% |
| >40 | 2 (discuss 3) | 10–25% | 5–20% |
Elective single embryo transfer (eSET) should be offered to all good-prognosis patients — under 38 with a good-quality embryo in a first transfer — because multiple pregnancy is the leading iatrogenic complication of ART. — ASRM guidance on the number of embryos transferred, 2024
Decision Node 7: Domestic or Cross-Border Care?
| Factor | Domestic | Cross-Border |
|---|---|---|
| IVF cost per cycle | $12,000–$18,000 (US) | $4,000–$9,000 (destinations) |
| Legal restrictions | Varies by country | Depends on destination |
| Continuity of care | Strong | Requires multiple trips |
| Additional costs | None | $2,000–$5,000 per trip (flights + hotel) |
Cross-border candidates face a home-country legal restriction (donor eggs, surrogacy, sex selection), are over 38, have ≥2 failed cycles, or lack the technique locally.
Decision Node 8: Assisted Hatching?
| Indicator | Score |
|---|---|
| Age ≥38 | +2 |
| ≥2 prior failed transfers (good embryos) | +2 |
| Frozen embryo transfer | +1 |
| Abnormal zona thickness | +2 |
| Average ICM grade (B or C) | +1 |
| Score ≥3: consider assisted hatching | — |
Decision Node 9: Remaining Embryos
| Option | Best For | Cost | Legal |
|---|---|---|---|
| Continued storage | Almost all cases | $300–$600/year | Allowed in most countries |
| Donate to research | No further family building | None | Informed consent |
| Donate to other couples | Completed family, willing | May involve compensation | Varies widely |
| Discard | Decision to stop | None | Time limits in some countries |
Decision Node 10: After a Failed Cycle — Adjust or Persist?
| Cycle Outcome | Recommended Action | Workup Needed |
|---|---|---|
| Fertilization failure | Switch to ICSI | Sperm DFI, egg maturity |
| Embryo arrest (no blastocyst) | Adjust protocol | Sperm DFI >30%, protocol, lab |
| Failed implantation | Endometrial protocol | Receptivity (ERA/ERS), immune |
| Biochemical/miscarriage | PGT-A if not done | Chromosomes, immune/coagulation |
| No live birth | Persist — 3-cycle cumulative >70% | — |
How Are ART Success Rates Trending?
Global ART cycles rose from ~3.2 million in 2024 (US >330,000, Europe >1 million) to a projected ~3.6 million in 2026, driven by delayed childbearing and expanding insurance coverage.
| Trend | 2024 | 2025 | 2026 (proj.) |
|---|---|---|---|
| eSET rate (global) | ~50% | ~55% | ~60% |
| AI embryo grading | ~20% | ~35% | ~50% |
| FET share (global) | ~55% | ~60% | ~65% |
| PGT-A use (>35) | ~30% | ~35% | ~40% |
Ranked by impact: female age (~40% of outcome variance), ovarian reserve (AMH/AFC), embryo chromosomal status (euploid birth 3–5× higher), lab quality (top labs 15–20 points higher blastulation), endometrial status, BMI (>30 cuts birth ~10–15%), and smoking.
| Technology | <35 | 35–37 | 38–40 | 41–42 | >42 |
|---|---|---|---|---|---|
| IUI (stimulated) | 12–18% | 8–12% | 3–8% | <3% | <1% |
| IVF (fresh) | 45–55% | 35–42% | 20–30% | 10–18% | 5–12% |
| IVF (FET, good blastocyst) | 50–58% | 38–45% | 22–32% | 12–20% | 6–14% |
| ICSI | 45–53% | 34–40% | 19–28% | 9–17% | 5–11% |
| PGT-A+FET (euploid) | 60–70% | 55–65% | 50–60% | 45–55% | 40–50% |
| Donor egg IVF | 50–60% | 50–60% | 50–60% | 45–55% | 40–55% |
All figures are per-transfer live birth rates; cumulative multi-cycle rates are significantly higher.
Five Patient ART Pathways
These anonymized composites illustrate pathway logic.
Case 1 — 32, unexplained infertility, IUI→IVF ladder. Sarah had patent tubes and AMH 3.0 ng/mL after 2 years trying. Three stimulated IUI cycles were negative (~$2,400), so she moved to IVF: 12 eggs → 10 fertilized → 7 blastocysts → 5 euploid on PGT-A → one 4AA transferred → pregnancy. Total ~$23,900.
Case 2 — 41, low AMH, direct donor egg. Jennifer, 41, had AMH 0.6 ng/mL and one failed own-egg cycle (3 eggs, 1 fertilized, no blastocyst). A donor-egg cycle (donor 25) gave 10 blastocysts, and a PGT-A-screened 4AA euploid transferred. Donor-egg birth (40–55%/cycle) far exceeds own-egg (5–12%) at her age. Package ~$18,000–$25,000.
Case 3 — 36, PCOS, freeze-all. Emily retrieved 20 eggs (E2 4,500 pg/mL) and chose freeze-all to avoid OHSS (15–25% in PCOS). A 4BB frozen embryo transferred 3 months later achieved pregnancy. Total ~$23,000.
Case 4 — 38, recurrent miscarriage, PGT-A. Amanda had 2 miscarriages, normal karyotype. PGT-A on 5 blastocysts returned 2 euploid, and a 4BB euploid transfer led to a healthy birth. At 38 aneuploidy runs 60%, so PGT-A ($3,500) avoided at least 2 ineffective transfers. Total ~$24,500.
Case 5 — 45, cross-border donor egg. Maria, AMH <0.1 ng/mL, had 2 failed own-egg cycles and chose a Greek donor program (donor 23, 8 blastocysts, 6 euploid). Above 45 own-egg birth is <5%/cycle vs 40–55% donor. Total ~$22,000–$30,000.
All cases are anonymized composites, not individual patients.
How Do You Evaluate an ART Lab?
The lab decides outcomes: time-lapse incubation (~20% better blastocyst selection), vitrification (>95% survival vs 60–80% slow-freeze), 5% low-oxygen culture (10–15% higher blastulation), NGS-PGT (>99% accuracy), and AI grading (~25% consistency gain).
| Item | High standard | Medium | Red flag |
|---|---|---|---|
| Incubator | Time-lapse | Standard + timed checks | Old, unmonitored |
| Blastulation (<35) | ≥60% | 45–59% | <45% |
| Thaw survival | ≥95% | 85–94% | <85% |
| Accreditation | CAP + JCI + ISO 15189 | JCI or equivalent | None |
| Annual PGT biopsies | ≥200 | 50–199 | <50 |
| ICSI fertilization | ≥80% | 70–79% | <70% |
Ask each clinic: incubator type, blastulation, thaw survival, annual PGT biopsies.
What Is Coming Next in ART from 2026 to 2030?
Five technologies are closest to practice: AI full-cycle optimization (a 2025 Nature Medicine model predicts implantation at AUC >0.85), non-invasive PGT (cell-free DNA in culture media, ~85–90% accuracy), in vitro gametogenesis (mice 2024, humans 10+ years away), mitochondrial replacement, and uterus transplantation (>100 pregnancies globally).
FAQ
Q: What is the difference between ART and IVF?
ART is the umbrella; IVF is one technique under it, not a synonym.
Q: Which “generation” of IVF is best?
They mark indications, not quality: IVF suits tubal or ovulation issues, ICSI male factor, PGT age or genetic problems — the choice follows your diagnosis, not “newer is better.”
Q: Why do ART success rates vary so much between countries?
Five reasons: reporting standards (pregnancy vs live birth), double-embryo transfers, patient age mix, lab quality, and legal limits on embryos transferred.
Q: How long does an ART cycle take?
IUI 2–4 weeks; fresh IVF 4–6 weeks; FET 8–16 weeks; donor-egg IVF 2–6 months; surrogacy 12–18 months.
Q: What are the biggest risks in ART?
Three lead: multiples (15–25% vs 1–2% naturally, preventable by eSET), severe OHSS (0.5–2%, reduced by freeze-all), and the psychological burden of a 30–60% per-cycle failure rate.
Q: Which success-rate metric should I compare?
From least to most flattering: live birth per retrieval (most honest), per transfer, clinical pregnancy (10–15% above live birth), biochemical (highest). Compare centers on one metric.
Q: Does ART have long-term effects on children?
In >12 million ART births, major defects run 3–4% vs 2–3% naturally, with no cognitive difference and no clear cancer increase; suggested ICSI epigenetic effects remain unclear.
Q: How do I evaluate a center’s real quality?
Ask 5 numbers: age-stratified live birth per retrieval, multiple rate, blastulation rate, thaw survival (>95%), and annual cycle volume (>500).
How Do You Plan Your ART Journey?
- Confirm the diagnosis and baseline — workup (AMH/AFC, tubes, cavity; semen analysis/DFI) plus your goals and constraints.
- Design the pathway — set the technique with the IUI-vs-IVF matrix, screen destinations with the quadrant model, then consult ≥2 centers.
- Decide in-cycle and review after each cycle — record retrieval, fertilization, blastulation, and outcome, then set the next step (Decision Node 10).
Compare destinations in our IVF hospital directory, read the IUI vs IVF guide or what is IVF, benchmark prices in the IVF cost comparison, and see the IVF procedure guide and success rates by age.
Content authorship: written by the ProIVF Medical Editorial Team and reviewed by the ProIVF Medical Advisory Board.
Informational only; not medical advice. Consult a qualified fertility specialist for personal guidance.
Last updated: July 26, 2026
